BIIB reports stronger-than-expected Q2 results, lifting full-year guidance amid revenue growth and product performance.
Biogen posted second-quarter non-GAAP earnings per share of $3.60, surpassing estimates by $1.57. Revenue reached $2.7 billion, a 3.8% year-over-year increase, beating expectations by $240 million.
SPINRAZA revenue grew 2% to $402 million, while VUMERITY revenue declined 7% to $197 million due to inventory dynamics. The company updated its FY26 outlook following the results.
The earnings beat and raised guidance reflect improved operational performance and product demand.